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Background: The prevalence of metabolic syndrome (MetS) is increasing, and obesity, insulin resistance, and in-
flammation are the known risk factors. However, results of previous studies regarding the relationship between 
MetS and inflammation have not been consistent. This study aimed to identify the associations between C-reactive 
protein (CRP) and MetS and its components in obese and non-obese men and women.
Methods: This was a cross-sectional study based on the 6th Korea National Health and Nutrition Examination Sur-
vey (2015), and a nationally representative sample of 3,013 Korean adults aged 40–78 years were included. Those 
with cardiovascular disease, cancer, CRP level >10 mg/L, white blood cell count >10,000/mm3, chronic kidney dis-
ease, and lung/liver disease were excluded.
Results: Approximately 11.0%, 50.0%, 8.4%, and 48.8% of non-obese men, obese men, non-obese women, and 
obese women presented with MetS (P<0.001), respectively. In all four groups, those who presented with MetS or its 
components showed a higher high-sensitivity (hs-CRP) average than those without. Multivariate regression analy-
sis showed the increased risk of developing MetS with higher quartiles of hs-CRP level in obese (3rd and 4th quar-
tiles: odds ratios [ORs], 3.87 and 2.57, respectively) and non-obese women (4th quartile: OR, 2.63). The different 
components also showed increased ORs in the four groups. However, no statistically significant trend in the rela-
tionship was found in men.
Conclusion: Low-grade inflammation may increase the risk of MetS in Korean women independent of adiposity. 
However, due to the cross-sectional design of the present study, further studies must be conducted to identify the 
causal relationship between inflammation and metabolic disorders.
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INTRODUCTION
Metabolic syndrome (MetS) is characterized by the presence of dyslip-
idemia, hyperglycemia, elevated blood pressure, and abdominal obe-
sity. Due to sedentary lifestyle and obesity, MetS has become one of 
the most common health issues globally.1) Approximately 20%–30% of 
adults in several countries have MetS.2) Numerous studies have shown 
that patients with MetS are more likely to develop diabetes mellitus 
and cardiovascular disease and die prematurely. Thus, the high preva-
lence of MetS has become a serious concern.3)
 MetS is thought to be correlated to a chronic low-grade inflammato-
ry response, which is characterized by overt cytokine production and 
inflammatory signaling pathways.4) It is also believed to be associated 
with obesity, adipokines, and insulin resistance.5-7) However, there has 
been a controversy regarding the cause and effect interrelationships 
and the extent of contribution of each factor, and to date, the exact 
pathway associated with the condition has yet to be explained.
 To the best of our knowledge, a national study evaluating the differ-
ence in the risk of MetS in terms of elevated C-reactive protein (CRP) 
level between obese and non-obese participants has not been con-
ducted, and only a few international studies that included western 
populations have been carried out. In addition, most of these studies 
are not stratified by gender. Results have been scattered and are con-
troversial. Thus, in this study, we aimed to investigate (1) the relation-
ship between high-sensitivity CRP (hs-CRP) and MetS and (2) whether 
the relationship is different between obese and non-obese men and 
women in a representative Korean population.
METHODS
1. Study Participants
The Korea National Health and Nutrition Examination Survey 
(KNHANES) is a nationwide health and nutrition survey conducted 
annually by the Korea Centers for Disease Control and Prevention 
(KCDC) to identify the general health behaviors and status of the 
South Korean population, the incidence of common chronic diseases, 
and comprehensive nutritional data.8) Between 2013 and 2015, the 6th 
KNHANES annually surveyed 3,840 households in 192 regions, which 
were representative of the Korean population. Recruitment of the par-
ticipants was conducted using a stratified, multistage cluster sampling 
method utilizing sampling units and households as 1st and 2nd sam-
pling units. Sampling units were chosen based on residential condi-
tion and geographical area, and then, 20 households from the units 
were selected using a systematic sampling method. Representability 
was ensured by assigning weight values to each participant for an 
equal probability of sampling.
 Health and nutrition surveys as well as physical examinations of the 
household members were carried out, and each member had different 
age restrictions. Hs-CRP and serum insulin levels were only measured 
in 2015. In this study, we excluded participants aged 40 years and older 
with cancer, cardiovascular diseases (myocardial infarction and 
stroke), chronic kidney disease, pulmonary disease (chronic obstruc-
tive pulmonary disease, asthma, and tuberculosis), liver disease (hep-
atitis B and C virus and liver cirrhosis), white blood cell (WBC) count 
>10,000/mm3, and CRP level >10 mg/L (possible acute infection). The 
median age of the participants was 56 years (range, 40–79 years). Fi-
nally, of the 7,380 participants, 3,013 were included in this national 
survey.
2. Data Collection
1) Survey
All participants who participated were asked to sign an informed con-
sent before data collection. Health surveys and physical examinations 
were conducted at mobile medical centers, and interviews were per-
formed by trained interviewers. Based on the results, we categorized 
income as high, upper-medium, lower-medium, and low and educa-
tion as below elementary school, middle school graduate, high school 
graduate, and above college graduate. We defined current drinkers as 
those who consumed alcohol more than once within the last month; 
smokers as current smokers (excluding ex-smokers); and moderate or 
vigorous physical activity (as compared to inactivity) as those who en-
gaged in more than 2.5 hours of middle-strength exercise or 1.25 hours 
of high-strength exercise, or in mixed exercise that is equivalent to the 
former (1-minute high-strength=2-minute middle-strength) in a week.
2) Anthropometric data
Physical examinations were performed by trained medical staff in ac-
cordance to standardized procedures. Weight and height were mea-
sured while the participants were wearing light clothing without shoes, 
and each were measured to the nearest 0.1 cm and 0.1 kg. Body mass 
index (BMI) was calculated according to the height and weight mea-
surements: BMI=body weight (kg)/height (m2). Waist circumference 
was measured to the nearest 0.1 cm at the midpoint between the mid-
axillary lower end of the last rib and the upper rim of the iliac crest af-
ter the participants exhaled.
 Blood pressure was manually measured 3 times at 30-second inter-
vals using a mercury sphygmomanometer (Baumanometer Desk 
Model 0320; WA Baum Co., Copiague, NY, USA) after resting for a min-
imum of 5 minutes in sitting position. The average value of the 2nd 
and 3rd measurements was recorded.
3) Laboratory measurements
Venous blood samples were collected after a minimum of 8-hour fast-
ing and were processed, immediately refrigerated, and placed in a cold 
storage while being transported to the central laboratory within 24 
hours. Serum high-density lipoprotein (HDL) cholesterol level was 
measured using the homogeneous enzymatic colorimetric method, 
and triglyceride (TG) and glucose levels were obtained using the enzy-
matic and hexokinase ultraviolet methods utilizing the Hitachi Auto-
matic Analyzer 7600-210 (Hitachi, Tokyo, Japan), respectively. Serum 
insulin level was measured using ECLIA (electrochemiluminescence 
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immunoassay), and hs-CRP level was measured with immunoturbi-
dimetry using the Cobas 8000 (Roche, Mannheim, Germany). WBC 
count was measured with flow cytometry using semiconductor lasers 
on the XE-2100D (Sysmex, Kobe, Japan) from 2013 to 2014 and the 
XN-9000 (Sysmex) in 2015.
3. Definition of Metabolic Syndrome and Obesity
MetS was defined according to the National Cholesterol Education 
Program Adult Treatment Panel III (NCEP-ATP III) criteria, with the 
exception of abdominal obesity based on waist circumference.9) We 
used the modified waist circumference cutoff point of >90 cm for men 
and >85 cm for women in this study.10) Accordingly, in this study, indi-
viduals who meet three or more of the following criteria were defined 
as having MetS: (1) waist circumference >90 cm for men or >85 cm for 
women, (2) high blood pressure (≥130/85 mm Hg) or intake of antihy-
pertensive medications, (3) elevated fasting glucose level (≥100 mg/
dL) or use of antidiabetic agents or insulin, (4) low HDL-cholesterol 
(HDL-C) level (<40 mg/dL for men or <50 mg/dL for women), and (5) 
hypertriglyceridemia (hyperTG ≥150 mg/dL). Obesity was defined as a 
BMI ≥25.0 kg/m2.11)
4. Insulin Resistance
Homeostatic model assessment of insulin resistance (HOMA-IR) was 
used for estimating insulin sensitivity and was calculated using the fol-
lowing formula:12) HOMA-IR=fasting insulin (μIU/mL)×fasting glucose 
(mg/dL)/405. We defined insulin resistance as a HOMA-IR score 
≥2.5.12)
5. Statistical Analysis
Statistical analyses were performed using the IBM SPSS software ver. 
23.0 (IBM Corp., Armonk, NY, USA). During the KNHANES, the KCDC 
used a complex sample design for unequal selection probabilities, 
stratification, and clustering. Sampling weights reflected non-response 
rate, post-stratification, and complex sample design. The composite 
sample weight was introduced into our analyses to provide represen-
tative estimates of the non-institutionalized Korean population. Natu-
ral log transformations were performed for hs-CRP level and HOMA-
IR score to approximate normality.
 We used the Rao-Scott chi-square test for categorical variables and 
analysis of variance (ANOVA) for continuous variables to evaluate the 
demographic characteristics of the population. Student t-test was used 
to analyze the mean CRP level, and ANOVA was utilized to obtain the 
mean HOMA-IR score according to the components of MetS and 
quartiles of hs-CRP level, respectively. Multivariate logistic regression 
was used to estimate the odds ratios (ORs) for MetS and its compo-
nents after adjusting for age, smoking, drinking, physical activity, edu-
Table 1. Demographic and clinical characteristics of the study participants*
Characteristic
Men Women
Total
Non-obese Obese Non-obese Obese
Total 740 (29.2) 450 (17.9) 1341 (40.4) 482 (12.5) 3013 (100.0)
Age (y) 40.06±0.57 41.62±0.67 41.84±0.47 50.24±0.78 42.32±0.36
Body mass index (kg/m2) 22.35±0.08 27.74±0.13 21.39±0.07 27.75±0.14 23.60±0.09
Height (cm) 172.00±0.27 172.54±0.36 159.13±0.20 156.77±0.33 164.99±0.20
Weight (kg) 66.20±0.32 82.81±0.55 54.16±0.21 68.40±0.53 64.58±0.30
Waist circumference (cm) 80.65±0.25 93.33±0.38 73.91±0.23 88.80±0.41 81.22±0.23
Systolic BP (mm Hg) 115.85±0.61 122.24±0.73 109.81±0.45 120.64±0.95 115.15±0.38
Diastolic BP (mm Hg) 76.20±0.41 80.65±0.58 71.04±0.29 76.67±0.56 74.97±0.26
Fasting glucose level (mg/dL) 97.08±0.86 101.33±1.05 92.56±0.43 100.89±1.01 96.49±0.41
TG level (mg/dL) 135.97±4.95 213.64±9.68 94.48±1.66 144.00±3.99 134.12±2.64
Total cholesterol level (mg/dL) 186.98±1.37 199.85±1.78 187.64±0.93 198.55±1.88 190.99±0.69
HDL level (mg/dL) 50.88±0.49 44.25±0.50 57.86±0.42 49.61±0.59 52.36±0.27
Serum insulin level (uIU/mL) 6.27±0.19 10.97±0.28 6.30±0.12 10.91±0.39 7.70±0.11
HOMA-IR score 1.53±0.05 2.81±0.09 1.48±0.03 2.87±0.15 1.90±0.03
High-sensitivity C-reactive protein level (mg/dL) 0.81±0.04 1.12±0.07 0.70±0.03 1.46±0.10 0.90±0.03
Smoking† 244 (36.0) 147 (36.3) 52 (4.3) 25 (6.2) 468 (19.5)
Drinking‡ 581 (80.4) 334 (74.7) 579 (46.1) 199 (45.1) 1693 (61.1)
Physical activity§ 420 (57.7) 249 (58.5) 629 (50.0) 207 (45.3) 1505 (53.2)
Insulin resistance (HOMA-IR score ≥2.5) 79 (10.8) 193 (46.0) 148 (9.6) 214 (44.9) 634 (20.9)
Abdominal obesity∥ 49 (5.3) 301 (66.6) 100 (6.3) 340 (69.2) 790 (24.7)
Hypertriglyceridemia¶ 204 (26.4) 240 (54.0) 203 (12.6) 179 (35.8) 826 (26.9)
Low HDL-cholesterol level** 125 (15.8) 140 (32.1) 428 (27.9) 277 (57.8) 970 (28.8)
Metabolic syndrome 103 (11.0) 238 (50.0) 159 (8.4) 254 (48.8) 754 (21.6)
Values are presented as mean±standard error or unweighted number (weighted %).
BP, blood pressure; TG, triglyceride; HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment of insulin resistance.
*P-value <0.001; calculated using Rao-Scott chi-square test for categorical variables and analysis of variance for continuous variables. †Current smokers. ‡Alcohol 
consumption more than once within the last month. §More than 2.5 hours of middle-strength or 1.25 hours of high-strength exercise a week. ∥Waist circumference >90 cm 
(men)/85 cm (women). ¶TG level ≥150 mg/dL. **HDL level <40 mg/dL (men)/50 mg/dL (women).
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cation, income, and BMI in the final model. Statistical tests were two-
sided, and a P-value <0.05 was considered statistically significant.
RESULTS
1. Characteristics of the Participants
The clinical characteristics of the four groups are shown in Table 1. 
Waist circumference, systolic and diastolic blood pressure, fasting glu-
cose level, and TG level were higher in the obese groups than in the 
non-obese groups, and men had higher values than women. The 
HOMA-IR score and hs-CRP level were highest in obese women and 
lowest in non-obese women. Approximately 11.0%, 50.0%, 8.4%, and 
48.8% of non-obese men, obese men, non-obese women, and obese 
women presented with MetS, respectively (P<0.001 for all aforemen-
tioned).
2. Distribution of High-Sensitivity C-Reactive Protein Level 
Based on the Presence and Absence of Each Component 
of MetS, MetS, and Insulin Resistance
The mean hs-CRP levels were higher in the presence of MetS or insu-
lin resistance (HOMA-IR score ≥2.5) in all four groups. In both non-
obese groups, hyperTG, low HDL-C level, and high fasting glucose lev-
el yielded higher hs-CRP level. Moreover, non-obese women showed 
a higher hs-CRP level and high blood pressure (P<0.001), while non-
obese men did not. In both obese groups, abdominal obesity correlat-
ed to higher hs-CRP level. Obese women showed higher hs-CRP level 
and hyperTG (P<0.05), and obese men had a high blood pressure 
(P<0.001) (Table 2).
3. Distribution of Homeostatic Model Assessment of Insulin 
Resistance Score according to the Quartiles of High-
Sensitivity C-Reactive Protein
The range and median of the HOMA-IR score are shown by the quar-
tiles of hs-CRP in Figure 1. In all four groups, the median value and up-
Table 2. Relationship between high-sensitivity C-reactive protein level and the presence of the components of metabolic syndrome, metabolic syndrome, and insulin resistance
Variable
Non-obese Obese
Present Absent Present Absent
Men
   Abdominal obesity 1.09 (0.54–1.65) 0.79 (0.71–0.88) 1.22 (1.02–1.41) 0.93 (0.76–1.10)
   Hypertriglyceridemia* 0.94 (0.77–1.11) 0.76 (0.66–0.86) 1.13 (0.95–1.31) 1.11 (0.90–1.31)
   Low HDL-cholesterol level* 1.07 (0.79–1.36) 0.76 (0.67–0.85) 1.32 (1.02–1.62) 1.03 (0.88–1.17)
   High fasting glucose level† 0.91 (0.75–1.08) 0.77 (0.67–0.87) 1.12 (0.96–1.29) 1.12 (0.91–1.32)
   High BP 0.76 (0.62–0.90) 0.83 (0.72–0.94) 1.27 (1.06–1.49) 0.98 (0.81–1.15)
   Metabolic syndrome† 1.00 (0.73–1.27) 0.79 (0.69–0.88) 1.28 (1.07–1.49) 0.96 (0.78–1.14)
   Insulin resistance (HOMA-IR score ≥2.5)† 1.06 (0.75–1.36) 0.78 (0.69–0.87) 1.36 (1.11–1.61) 0.91 (0.79–1.04)
Women
   Abdominal obesity‡ 0.81 (0.47–1.14) 0.69 (0.63–0.76) 1.67 (1.44–1.89) 0.99 (0.72–1.27)
   Hypertriglyceridemia 0.80 (0.66–0.94) 0.69 (0.62–0.76) 1.51 (1.27–1.76) 1.43 (1.17–1.69)
   Low HDL-cholesterol level 0.98 (0.82–1.15) 0.59 (0.53–0.65) 1.49 (1.25–1.74) 1.41 (1.11–1.71)
   High fasting glucose level 0.94 (0.74–1.13) 0.66 (0.59–0.73) 1.51 (1.26–1.76) 1.43 (1.16–1.69)
   High BP† 0.87 (0.68–1.05) 0.67 (0.60–0.74) 1.33 (1.09–1.56) 1.56 (1.29–1.84)
   Metabolic syndrome† 1.07 (0.79–1.36) 0.67 (0.60–0.73) 1.49 (1.26–1.71) 1.43 (1.11–1.75)
   Insulin resistance (HOMA-IR score ≥2.5)* 0.99 (0.74–1.24) 0.67 (0.60–0.74) 1.72 (1.45–2.00) 1.24 (1.01–1.48)
Values are presented as mean (95% confidence interval). Abdominal obesity, waist circumference >90 cm (men)/85 cm (women); hypertriglyceridemia, triglyceride level ≥150 
mg/dL; low HDL-cholesterol, HDL level <40 mg/dL (men)/50 mg/dL (women); high fasting glucose level, fasting glucose level ≥100 mg/dL or use of antidiabetic agents or 
insulin; high BP, BP ≥130/85 mm Hg or intake of antihypertensive medications; metabolic syndrome, meeting 3 or more of the 5 aforementioned criteria.
HDL, high-density lipoprotein; BP, blood pressure; HOMA-IR, homeostatic model assessment of insulin resistance.
†P-value <0.01, *P-value <0.001, ‡P-value <0.05; calculated using Student t-test.
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Figure 1. Distribution of the HOMA-IR score according to quartiles of hs-CRP level. 
Values are shown in a box and whisker plot. The mean HOMA-IR score for the 1st, 
2nd, 3rd, and 4th quartiles of hs-CRP level were 1.26, 1.42, 1.57, and 1.81 for the 
male non-obese group (P-trend 0.001) and 2.21, 2.66, 3.27, and 3.18 for the male 
obese group (P-trend<0.001) as well as 1.32, 1.34, 1.45, and 1.74 for the female 
non-obese group (P-trend<0.001) and 2.45, 2.50, 2.92, and 3.55 for the female 
obese group, respectively (P-trend 0.006). Calculation was conducted using analysis 
of variance. HOMA-IR, homeostatic model assessment of insulin resistance; hs-CRP, 
high-sensitivity C-reactive protein.
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per inner fence showed a general tendency toward a gradual linear in-
crease with each increasing quartile. The median and range of the 
HOMA-IR score is higher in the obese group than in the non-obese 
group in terms of all quartiles for both genders. The mean HOMA-IR 
score for those in the 1st, 2nd, 3rd, and 4th quartiles of hs-CRP level 
were 1.26, 1.42, 1.57, and 1.81 for the male non-obese group (P-
trend=0.001) and 2.21, 2.66, 3.27, and 3.18 for the male obese group (P-
trend <0.001) as well as 1.32, 1.34, 1.45, and 1.74 for the female non-
obese group (P-trend <0.001) and 2.45, 2.50, 2.92, and 3.55 for the fe-
male obese group (P-trend=0.006), respectively. Thus, a dose–re-
sponse relationship could be inferred across all the quartiles of hs-CRP 
level and HOMA-IR score, regardless of gender or obesity status.
4. Association between High-Sensitivity C-Reactive Protein 
Level as well as Metabolic Syndrome and Its Components
The ORs of MetS and its components according to the quartiles of hs-
CRP level are shown in Table 3 using the 1st quartile as reference. In 
non-obese women, a higher risk for MetS (4th quartile: 2.63, 1.28–
5.39), hyperTG (4th quartile: 1.90, 1.08–3.35), and low HDL-C level 
(2nd quartile: 1.76, 1.18–2.61 and 4th quartile: 3.54, 2.29–5.48) was ob-
served. In obese women, an increased risk was also identified for MetS 
(3rd quartile: 3.87, 1.55–9.64 and 4th quartile: 2.57, 1.08–6.09), low 
HDL-C (3rd quartile: 5.07, 1.71–15.06 and 4th quartile: 3.21, 1.16–8.90), 
and abdominal obesity (4th quartile: 2.84, 1.16–6.96) (P-trend <0.05 for 
all aforementioned). In non-obese men, associations between hyper-
TG, low HDL-C level, and high fasting glucose level were found. Mean-
while, in obese men, the risk for high blood pressure was noted. How-
ever, no significant relationship was observed between the risk for high 
blood pressure and MetS or stepwise gradient (P-trend not significant).
Table 3. Adjusted odds ratio for metabolic syndrome and its components according to obesity-specific quartiles of CRP
Variable P for trend 1st quartile 2nd quartile 3rd quartile 4th quartile
Men, non-obese
   Quartiles of hs-CRP level ≤0.30 0.30–0.50 0.50–0.80 >0.80
   Abdominal obesity 0.89 1 1.54 (0.42–5.62) 1.09 (0.40–2.97) 1.38 (0.40–4.72)
   Hypertriglyceridemia 0.14 1 1.48 (0.86–2.53) 1.85 (0.98–3.47) 1.92 (1.05–3.50)*
   Low HDL-cholesterol level 0.09 1 1.61 (0.86–3.02) 2.02 (1.06–3.83)* 2.51 (1.20–5.22)* 
   High fasting glucose level 0.10 1 1.79 (1.06–3.01)* 1.78 (0.99–3.21) 1.83 (0.96–3.46)
   High BP 0.10 1 0.72 (0.41–1.28) 0.71 (0.40–1.26) 0.72 (0.37–1.26)
   Metabolic syndrome 0.55 1 1.37 (0.63–2.99) 1.70 (0.82–3.50) 1.58 (0.58–4.27)
Men, obese
   Quartiles of hs-CRP level ≤0.50 0.50–0.70 0.70–1.20 >1.20
   Abdominal obesity 0.72 1 1.05 (0.49–2.28) 0.75 (0.32–1.80) 0.70 (0.28–1.76)
   Hypertriglyceridemia 0.52 1 1.49 (0.66–3.37) 1.50 (0.73–3.07) 1.07 (0.52–2.22)
   Low HDL-cholesterol level 0.33 1 0.50 (0.21–1.17) 0.85 (0.39–1.83) 0.64 (0.29–1.42)
   High fasting glucose level 0.32 1 0.56 (0.26–1.21) 0.76 (0.39–1.49) 1.01 (0.51–2.03)
   High BP 0.11 1 1.88 (0.89–3.99) 2.04 (1.08–3.86)* 2.24 (1.08–4.64)*
   Metabolic syndrome 0.32 1 0.77 (0.35–1.68) 1.37 (0.67–2.80) 1.07 (0.50–2.29)
Women, non-obese
   Quartiles of hs-CRP level ≤0.30 0.30–0.40 0.40–0.70 >0.70
   Abdominal obesity 0.45 1 0.58 (0.21–1.63) 0.97 (0.34–2.79) 0.57 (0.21–1.52)
   Hypertriglyceridemia <0.01 1 0.95 (0.52–1.72) 1.27 (0.64–2.50) 1.90 (1.08–3.35)*
   Low HDL-cholesterol level <0.01 1 1.76 (1.18–2.61)† 1.52 (0.89–2.60) 3.54 (2.29–5.48)‡
   High fasting glucose level 0.12 1 0.78 (0.51–1.20) 1.26 (0.71–2.24) 1.25 (0.77–2.05)
   High BP 0.47 1 1.26 (0.74–2.16) 0.84 (0.46–1.53) 1.21 (0.66–2.21)
   Metabolic syndrome 0.01 1 1.12 (0.53–2.34) 1.68 (0.75–3.77) 2.63 (1.28–5.39)†
Women, obese
   Quartiles of hs-CRP level ≤0.50 0.50–0.80 0.80–1.70 >1.70
   Abdominal obesity 0.01 1 1.02 (0.37–2.77) 1.69 (0.58–4.97) 2.84 (1.16–6.96)*
   Hypertriglyceridemia 0.02 1 0.94 (0.32–2.72) 1.79 (0.62–5.17) 2.22 (0.87–5.69)
   Low HDL-cholesterol level 0.01 1 2.31 (0.79–6.81) 5.07 (1.71–15.06)† 3.21 (1.16–8.90)*
   High fasting glucose level 0.74 1 0.71 (0.27–1.86) 0.62 (0.23–1.64) 0.81 (0.32–2.05)
   High BP 0.57 1 0.83 (0.33–2.06) 1.04 (0.36–3.03) 0.65 (0.25–1.67)
   Metabolic syndrome 0.01 1 1.44 (0.54–3.86) 3.87 (1.55–9.64)† 2.57 (1.08–6.09)*
Values are presented as hs-CRP quartile ranges (mg/dL) or odds ratio (95% confidence interval), unless otherwise stated. Adjusted for age, education, smoking, alcohol, body 
mass index, income, and physical activity. Abdominal obesity, waist circumference >90 cm (men)/85 cm (women); hypertriglyceridemia, TG level ≥150 mg/dL; low HDL-
cholesterol level, HDL-cholesterol level <40 mg/dL (men)/50 mg/dL (women); high fasting glucose, fasting glucose level ≥100 mg/dL or use of antidiabetic agents or insulin; 
high BP, blood pressure ≥130/85 mm Hg or use of antihypertensive medications; metabolic syndrome, meeting 3 or more of the 5 aforementioned criteria.
CRP, C-reactive protein; hs-CRP, high-sensitivity CRP; HDL, high-density lipoprotein; BP, blood pressure.
*P-value <0.05, †P-value <0.01, ‡P-value <0.001; calculated using the logistic regression model for odds ratios.
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DISCUSSION
In Korea, data from the KNHANES indicate that the prevalence of 
MetS increased from 24.9% in 1998 to 31.3% in 2007 among Korean 
adults,13) and based on our study, it further increased to 34% in the 
middle-aged and elderly population in 2015. The overall prevalence of 
MetS is higher in obese individuals. However, not all obese individuals 
present with a clustering of metabolic and/or cardiovascular risk fac-
tors. Moreover, lean individuals also present with the features of 
MetS.14) The exact mechanism in which MetS develops in certain indi-
viduals and not in others is not yet understood, and it is a subject of 
debate. The biggest known pillars are (visceral) adiposity and insulin 
resistance, which are both interrelated. Adipose tissue releases excess 
free fatty acids (FFA), adipokines, and angiotensin II. FFA and angio-
tensin II inhibit muscular glucose uptake and damages the pancreas, 
which leads to insulin resistance. Excess FFA and hyperglycemia leads 
to hyperTG, which in turn decreases HDL-C level. Angiotensin II has 
vasoconstrictive effects that increases blood pressure and adipokines, 
such as tumor necrosis factor-a (TNF-a), and interleukins induce in-
flammatory reactions that also inhibit insulin and induce hyperten-
sion and endothelial dysfunction in a vicious cycle.3) In more recent 
studies, low-grade chronic inflammation (CRP level <10 mg/L) has in-
dependently increases the risk of cardiovascular diseases,15) including 
MetS, and have been proposed as a method to improve risk prediction.
 Only a few studies have evaluated the difference in the relationship 
between hs-CRP level and MetS in obese and non-obese individuals. 
However, the results are controversial. Meanwhile, national studies 
have not been conducted. In addition, among these studies, only few 
were stratified by gender; most were adjusted for gender, and only one 
was stratified by sex. This study was conducted to evaluate the rela-
tionship between MetS and hs-CRP level and to identify a difference in 
the association between these four groups: obese and non-obese men 
and women.
 Our study showed that hs-CRP level plays a major role in the devel-
opment of MetS independent of adiposity in women. A positive asso-
ciation was found between hyperTG and low HDL-C level in both 
obese and non-obese women across the quartiles of hs-CRP level, and 
no significant change was observed in terms of the risks after adjusting 
for BMI. However, in men, after adjusting for BMI, the strong positive 
associations between hs-CRP level and hyperTG, low HDL-C, high 
fasting glucose level, and MetS (data not shown) were attenuated and 
some were annulled. Although hyperTG and low HDL-C level mildly 
increased the risk in terms of the higher quartiles of the non-obese 
participants and high blood pressure in obese individuals, no statisti-
cally significant linear tendency was observed in our final model that 
included BMI. Our finding is in accordance with those of the study on 
Mexicans by Han et al.16) that was stratified by gender and adiposity. 
Pradhan et al.17) have also found that hs-CRP level is independently as-
sociated with hyperinsulinemia in both overweight and lean Cauca-
sian women. However, men were not included in the study. Our data 
also suggests a linear gradient relationship between hs-CRP level and 
insulin resistance (surrogated by the HOMA-IR score) in all genders 
and obesity status, which is in accordance to the results of prior stud-
ies.18) Thus, in men, BMI or adiposity may play the most significant role 
in the pathogenesis of MetS.
 Studies regarding the relationship between inflammation and MetS 
have shown inconsistent results, particularly when stratified by gender 
and/or adiposity. Several recent studies have shown that subclinical 
inflammation plays an independent role in MetS. However, several 
studies have also shown attenuation or disappearance of significant 
associations after adjusting for adiposity or insulin resistance. In terms 
of obesity status, our study showed results similar to those of several 
other studies. In women and men before adjusting for BMI, similar as-
sociations were observed in both obese and non-obese individuals in 
studies conducted by Laaksonen et al.,19) McLaughlin et al.,20) and 
Stenholm et al.21) Other studies have shown varying amounts of asso-
ciation depending on obesity status, of which some are positive corre-
lated to BMI and some are not.7,16,22-25)
 Previous studies on the relationship between inflammation and 
MetS/insulin resistance based on gender differences were also contro-
versial, although most studies showed stronger associations in women 
than in men, which is similar our result.26) For example, Hoekstra et al. 
have found that CRP was associated with the components of MetS in 
elderly Dutch obese women but not in non-obese women, and similar 
but less pronounced results were shown in men.15) Moreover, Lai et al. 
have shown that hs-CRP level may be important in the development 
of MetS, particularly in women.27) Ryu et al.6) has conducted a study on 
1,578 Koreans from rural areas in 2006, and results showed that hs-
CRP level was associated with MetS only in men but not in women, 
which is in contrast to our study result. However, the participants who 
took voluntary health examinations were from rural areas; thus, it was 
not a proper representative sample of Koreans.
 There are several possible explanations behind our observation. 
First, subclinical inflammation may have a greater role in inhibiting 
the actions of insulin in women due to differences in sex hormones. 
For instance, inflammation may interact with female sex hormones 
and reduce the protective effects of estrogen on fat distribution and in-
sulin action. Previous studies have shown that cytokines may interfere 
with estradiol secretion,28) and oral estrogen may increase CRP lev-
els.29) Second, a higher number of female participants was analyzed, 
thus obtaining greater statistical power. Third, hs-CRP level could be 
merely a reflection of other more potent visceral adipokines, as similar 
as BMI in women have more fat mass and abdominal distribution, 
thus more interleukin-1, interleukin-6, and TNF-a are released, which 
do not only induce the hepatic synthesis of CRP but also various in-
flammatory effects.30) In relation to this, visceral adipocytokines are 
more potent, and they cause chronic inflammation compared to other 
inflammatory mediators. Fourth, while we divided the quartiles of 
CRP separately for obese and non-obese participants, most studies 
used a common division of CRP, such as the study by Ye et al.,7) and 
this indicates that our model was more detailed and intricate. Finally, 
since there were no studies on the Korean population, it might be due 
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to a racial/genetic difference in the predisposition to MetS.
 Our study has several strengths. To the best of our knowledge, this is 
the first large-scale, population-based study that investigated CRP dis-
tribution and its relation with updated NCEP-ATP III criteria for MetS 
among obese and non-obese individuals in Korea, and this study is 
among the few studies that were additionally stratified by gender 
worldwide. In addition, most confounding factors for the risk of MetS 
in this study were cautiously taken into consideration. The present 
study used the most recent data. However, the present study also had 
some limitations. CRP levels differ in terms of anti-inflammatory drugs 
and diet, which could not be considered due to limitations in research 
data. Moreover, total body fat mass or body fat composition based on 
the total or visceral depots was not evaluated for the same reason; 
Thus, a discrimination of lean but metabolically obese individuals and 
vice versa was not possible. Finally, the cross-sectional design does not 
allow for the discrimination of whether inflammation is a cause or a 
result of MetS and/or obesity and insulin resistance.
 In conclusion, based on our study, low-grade inflammation impor-
tant the pathogenesis of MetS in women, regardless of obesity status. 
We can also argue that such association was not found in men, and 
rather, BMI may be the most significant risk factor. Thus, we may need 
to pay close attention to inflammatory markers in women, and actively 
controlling low-grade inflammation may be beneficial in the preven-
tion and management of metabolic disorders. Specific actions for such 
condition may include the usage of statins and angiotensin-converting 
enzyme inhibitors, aspirin, and insulin-sensitizing agents, such as thi-
azolidinedione, and physical exercise. In addition, since we observed 
strong associations in both obese and non-obese women, CRP evalua-
tion could identify a broader group of individuals who might be at high 
risk of metabolic disorders, irrespective of weight. Since hs-CRP level 
is the most standardized and commonly used inflammatory marker, it 
could be of clinical value in predicting and monitoring MetS in wom-
en. More detailed studies must be conducted before firm conclusions 
can be drawn, particularly regarding sex differences.
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